Jeffery L. Kutok
Plus aucun poste en cours
Historique de carrière de Jeffery L. Kutok
Anciens postes connus de Jeffery L. Kutok
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| EPIZYME, INC. | Directeur Technique/Scientifique/R&D | 23/03/2020 | 01/09/2022 |
| INFINITY PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 01/01/2010 | 31/03/2020 |
The Brigham & Women's Hospital, Inc.
 The Brigham & Women's Hospital, Inc. Hospital/Nursing ManagementHealth Services The Brigham & Women's Hospital, Inc. provides health care services. The firm offers treatment for cancer, cardio vascular, neurosciences, orthopedic, arthritis, women's health and clinical services. The company was founded in 1980 and is headquartered in Boston, MA. | Corporate Officer/Principal | 01/01/2002 | 01/12/2010 |
| Harvard Medical School | Corporate Officer/Principal | 01/01/2002 | 01/12/2010 |
Formation de Jeffery L. Kutok
| Stony Brook University | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 6 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 3 |
| Health Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| INFINITY PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
The Brigham & Women's Hospital, Inc.
The Brigham & Women's Hospital, Inc. Hospital/Nursing ManagementHealth Services The Brigham & Women's Hospital, Inc. provides health care services. The firm offers treatment for cancer, cardio vascular, neurosciences, orthopedic, arthritis, women's health and clinical services. The company was founded in 1980 and is headquartered in Boston, MA. | Health Services |
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
- Bourse
- Insiders
- Jeffery L. Kutok
- Expérience